Print Page      Close Window     

SEC Filings

10-Q
ATHENEX, INC. filed this Form 10-Q on 05/09/2019
Entire Document
 

 

Disaggregation of revenue

The following represents the Company’s revenue for its reportable segment by country, based on the locations of the customer.

 

 

 

For the Three Months Ended March 31, 2019

 

 

 

(In Thousands)

 

 

 

Oncology

Innovation

Platform

 

 

Global Supply

Chain Platform

 

 

Commercial

Platform

 

 

Consolidated

Total

 

United States

 

$

 

 

$

5,660

 

 

$

14,675

 

 

$

20,335

 

India

 

 

 

 

 

777

 

 

 

 

 

 

777

 

Austria

 

 

 

 

 

2,173

 

 

 

 

 

 

2,173

 

China

 

 

144

 

 

 

242

 

 

 

 

 

 

386

 

United Kingdom

 

 

 

 

 

1,023

 

 

 

 

 

 

1,023

 

Other foreign countries

 

 

 

 

 

613

 

 

 

 

 

 

613

 

Total revenue

 

$

144

 

 

$

10,488

 

 

$

14,675

 

 

$

25,307

 

 

 

 

For the Three Months Ended March 31, 2018

 

 

 

(In Thousands)

 

 

 

Oncology

Innovation

Platform

 

 

Global Supply

Chain Platform

 

 

Commercial

Platform

 

 

Consolidated

Total

 

United States

 

$

 

 

$

1,208

 

 

$

8,694

 

 

$

9,901

 

India

 

 

 

 

 

962

 

 

 

 

 

 

962

 

Austria

 

 

 

 

 

1,243

 

 

 

 

 

 

1,243

 

China

 

 

231

 

 

 

417

 

 

 

 

 

 

648

 

Spain

 

 

25,000

 

 

 

 

 

 

 

 

 

25,000

 

Other foreign countries

 

 

 

 

 

82

 

 

 

 

 

 

82

 

Total revenue

 

$

25,231

 

 

$

3,911

 

 

$

8,694

 

 

$

37,836

 

 

The Company also disaggregates its revenue by product group which can be found in Note 13 – Business Segment, Geographic, and Concentration Risk Information.

Contract balances

The following table provides information about receivables and contract liabilities from contracts with customers. The Company has not recorded any contract assets from contracts with customers.

 

 

 

March 31,

2019

 

 

December 31,

2018

 

 

 

(In Thousands)

 

Accounts receivable, gross

 

$

31,032

 

 

$

26,061

 

Chargebacks and other deductions

 

 

(10,448

)

 

 

(13,101

)

Allowance for doubtful accounts

 

 

(8

)

 

 

(9

)

Accounts receivable, net

 

$

20,576

 

 

$

12,951

 

Deferred revenue

 

 

131

 

 

 

190

 

Total contract liabilities

 

$

131

 

 

$

190

 

 

The following tables illustrate accounts receivable balances by reportable segments.

 

 

 

March 31, 2019

 

 

 

(In Thousands)

 

 

 

Oncology

Innovation

Platform

 

 

Global Supply

Chain

Platform

 

 

Commercial

Platform

 

 

Consolidated

Total

 

Accounts receivable, gross

 

$

 

 

$

7,876

 

 

$

23,156

 

 

$

31,032

 

Allowance for doubtful accounts, chargebacks, and

   other deductions

 

 

 

 

 

(13

)

 

 

(10,443

)

 

 

(10,456

)

Accounts receivable, net

 

$

 

 

$

7,863

 

 

$

12,713

 

 

$

20,576

 

20